Categories AlphaGraphs, Earnings, Health Care

REGN Earnings: Regeneron Pharma reports higher Q2 profit and revenue

Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the second quarter of 2023.

Regeneron Pharmaceuticals Q2 2023 earnings infographic

June quarter revenues grew 11% year-over-year to $3.16 billion. Net product sales, which account for more than 50% of total revenues, edged up 1%.

Adjusted earnings moved up 5% to $10.24 per share in Q2 from $9.77 per share in the same period of 2022. Unadjusted profit was $968 million or $8.50 per share, compared to $852 million or $7.47 per share last year.

“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer,” said the company’s CEO Leonard Schleifer.

Prior Performance

  • Regeneron Pharmaceuticals Q4 2022 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

AAPL Earnings: Apple’s Q2 sales and profit beat estimates; iPhone sales down 10%

Apple Inc. (NASDAQ: AAPL) on Thursday reported better-than-expected profit and revenue for the second quarter of 2024. There was a 10% decrease in iPhone sales. The gadget giant reported revenues

Shopify (SHOP) is all set to report Q1 2024 results. Here’s what to expect

Over the years, Shopify Inc. (NYSE: SHOP) has steadily expanded its footprint in the online retail market through constant innovation, like the recent launch of a mobile POS device for

eBay (EBAY): A look at how the ecommerce company fared in Q1 2024

Shares of eBay Inc. (NASDAQ: EBAY) were down over 2% on Thursday. The company reported its earnings results for the first quarter of 2024 a day ago, with revenue and

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top